Senator David Perdue Tours Athens Animal Health Facility

Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment

ATHENS, GA – U.S. Senator David Perdue (R-GA) toured Boehringer Ingelheim Animal Health USA Inc.’s manufacturing and research facility in Athens, Georgia to mark completion of their expansion after a $76 million investment in the site. The investment doubled the company’s capacity to produce vaccines for pets in the United States and around the world.

Click here or below to download photos.

1010 pr

“Boehringer Ingelheim continues to be a strong contributor to our economy,” said Senator Perdue. “Their investment in Georgia is a testament to our outstanding universities, growing biosciences industry, and business-friendly climate. Boehringer Ingelheim’s products help support Georgia’s critical agriculture industry, and I personally want to congratulate the company and its employees on completing this expansion in Athens.”

“Today’s announcement is representative of the growth and investment Boehringer Ingelheim is making around the United States. It also signals our commitment to a world in which no animal suffers from preventable disease,” said Everett Hoekstra, president of Boehringer Ingelheim Animal Health USA Inc. “We are excited about what’s in store for our company and our communities, and for the future of animal health.”

The animal health company is headquartered in Duluth, Georgia, and employs about 440 people in Athens. The site produces more than 150 vaccines for pets, poultry, and wildlife sold in more than 80 countries, protecting animals from diseases like rabies.


 When Senator Perdue was elected, he was the only Fortune 500 CEO in Congress. He is serving his first term in the United States Senate, where he represents Georgia on the Armed Services, Banking, Budget, and Agriculture Committees.